The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.
 
Li Zhou
No Relationships to Disclose
 
Edward Hsiao
No Relationships to Disclose
 
Serigne N Lo
No Relationships to Disclose
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Merck Serono; Moderna Therapeutics; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi
 
George Au-Yeung
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)
 
Maria Gonzalez
No Relationships to Disclose
 
Andrew John Spillane
No Relationships to Disclose
 
Thomas Pennington
No Relationships to Disclose
 
Julie R. Howle
No Relationships to Disclose
 
Kerwin Frank Shannon
No Relationships to Disclose
 
Rony Kapoor
No Relationships to Disclose
 
Jonathan Stretch
No Relationships to Disclose
 
David E. Gyorki
Honoraria - BMSi; MSD Oncology; Novartis
Travel, Accommodations, Expenses - Amgen
 
Robyn P.M. Saw
Honoraria - BMS GmbH & Co. KG; Merck Sharp & Dohme; Novartis; Qbiotics
Consulting or Advisory Role - MSD; Qbiotics
Speakers' Bureau - Bristol-Myers Squibb/Sanofi; Novartis
Research Funding - Qbiotics
 
Sydney Ch'ng
No Relationships to Disclose
 
Richard A Scolyer
Employment - Sydney Local Health District / Royal Prince Alfred Hospital
Leadership - Melanoma Institute Australia
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); Evaxion Biotech; GlaxoSmithKline; IO Biotech; Merck Sharp & Dohme; metaoptima; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; Novartis; Novartis; Provectus Biopharmaceuticals; QBiotics; Roche
Research Funding - Melanoma Research Alliance (MRA); National Health and Medical Research Council; National Health and Medical Research Council; Tour de Cure
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche